Care at Milton S. Hershey Medical Center

Our clinic is recognized by the ALS Association as a Certified Treatment Center of Excellence that evaluates and treats ALS and related conditions. About 80 new patients with ALS are diagnosed at the center every year, and more than 230 are followed long-term at any given time.

What is ALS?

In ALS, the cells that control muscles, called motor neurons, waste away and no longer send messages to the muscles. Over time, this leads to the muscles getting weak. The arms, legs, mouth and tongue muscles stop working. When the muscles in the chest stop working, it becomes hard or impossible to breathe.

Causes of ALS

About one out of 10 cases of ALS are inherited because of a flaw in a family’s genes. Having a close family member with ALS raises the chances of having the disease. Other risks include military service and heavy contact with some pesticides (insect killers). In most cases, the cause isn’t known.

What to expect

Patients coming to us for the first time see a neurologist (nervous system doctor) who is an expert in ALS. The goal is to be as sure as possible about a diagnosis.

After doing a series of tests, the neurologist will make an appointment with you, your family and other caregivers to talk about the diagnosis. If you have ALS, the doctor will give information and talk about proven and trial treatments.

An ALS nurse specialist is often at that visit as well. If not, you’ll schedule a follow-up visit with a nurse specialist. The neurologist and nurse work with you and your family on a plan to treat the disease and manage symptoms.

Follow-up visits

Patients with ALS are seen about once every three months in our multidisciplinary clinic, which includes various specialists on our team. During these appointments, you and your family stay in one examining room for about three to four hours while the different team members meet with you.

At these visits, you will always have your weight and breathing capacity measured and see the neurologist and nurse. You will also see some or all of these team members

  • Physical therapist
  • Occupational therapist
  • Speech therapist
  • Registered dietician 
  • Respiratory therapist
  • Mental health specialist
  • Social worker
  • Pastoral care counselor

Which team members you will see during those visits is based on the issues you may be having at that time. 

Working with the primary care doctor

Patients need to keep seeing their own primary care doctor while using the ALS Clinic's specialized services. After each ALS Clinic visit, your primary care doctor gets a written update from your neurologist and a summary of what the ALS team recommends.

Goals of the Penn State ALS Clinic

  • Serve as a center to diagnose, treat and provide follow-up care to patients with ALS.
  • Work with primary care doctors to treat the patient.
  • Focus on special services for patients with ALS and related health problems.
  • Take a team approach to help patients function to their best ability.
  • Give each patient information about the disease process.
  • Offer therapeutic drug trials.
  • Keep patients and families aware of research, including research in our own Motor Neuron Disease Research Center. 

Learn more about the ALS care team.

Groups, Classes & Support

We’re thankful for the support we receive from a variety of sources. Without them, the ALS Clinic couldn’t further its missions.

We gratefully recognize the many private donations we have received from our patients and their families and friends.

Would you like to support our efforts?

Donations to support the Penn State Health ALS Center can be made to The ALS Association Greater Philadelphia Chapter.

Or if you’d like to support our clinical or research work by making a donation directly to our Center, you can write a check payable to the Pennsylvania State University, ALS Clinic, and send it to:

Zachary Simmons, MD
Director, Penn State Health ALS Center
Penn State Health Milton S. Hershey Medical Center
Department of Neurology, EC 037

Research & Clinical Trials

We strongly believe that research into what causes ALS and other motor neuron diseases will be the key to more effective treatments and to a cure. We also believe that research can lead to a better understanding of what can help improve quality of life for patients with ALS and their families.

The Penn State ALS Clinic and Research Center is funded by ALS Association Greater Philadelphia Chapter, Campbell Fund for ALS Research and many other individuals and groups.

We carry out our studies at several levels:

  • Clinical trials of medicines that show promise for treating ALS
  • Clinical research to improve the care and support of patients and their caregivers
  • Basic science research on:
    • Genetics
    • Biomarkers
    • Oxidative stress
    • Iron metabolism
    • Other causes that may explain how ALS develops

Inspired to Cure: Finding New Treatments for ALS


Clinical research faculty

Zachary Simmons, MD
Professor, Departments of Neurology and Humanities
Director, ALS Center

Stephen Schiff, MD, PhD
Brush Chair Professor of Engineering
Professor, Department of Neurosurgery

Andrew Geronimo, PhD
Assistant Professor, Department of Neurosurgery

Stephanie Felgoise, PhD
Professor and Vice-Chair, Department of Psychology
Philadelphia College of Osteopathic Medicine

Susan Walsh, RN, MSN, ACNS-BC
Regional Nurse Manager
ALS Association Greater Philadelphia Chapter

Anne Haulman, MPH
Neuromuscular Research Project Manager

Basic science research faculty

James Connor, PhD
University Distinguished Professor
Vice-Chair, Department of Neurosurgery

James Broach, PhD
Chairman, Biochemistry and Molecular
Biology Director, Institute for Personalized Medicine

Clinical research studies at Penn State

Actemra® (tocilizumab)

Tocilizumab is Food and Drug Administration (FDA)-approved to treat refractory (resists treatment) moderate to severe rheumatoid arthritis. This medicine is delivered into the veins by monthly infusion. Our clinic is taking part in a multicenter, randomized, double-blind, placebo-controlled 16-week study that evaluates how safe and tolerable tocilizumab is for people who have sporadic ALS.

FORTITUDE Study (CK-107)

Our clinic is a participating site in a multicenter clinical trial examining the investigational medication CK-2127107. CK-2127107 is being investigated as a potential new therapy for the improvement of skeletal muscle function in conditions associated with muscle weakness or fatigue such as ALS.


The Penn State Hershey Medical Center is a participating site in a multicenter clinical trial examining the investigational medication FLX-787-ODT. The purpose of this research study is to investigate the efficacy of FLX-787-ODT in treating muscle cramps in people with motor neuron disease (MND), including ALS (amyotrophic lateral sclerosis), PLS (primary lateral sclerosis), and PMA (progressive muscular atrophy).

GTAC Study

The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.


The Penn State Hershey Medical Center is a participating site in a multicenter clinical trial investigating the drug mexiletine as a potential new therapy for ALS. We are doing this research study to find out whether mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves of people with ALS. We will also determine if there are any signs that the drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching (fasciculations). Mexiletine is already approved by the Food and Drug Administration (FDA) for other purposes.

PARADIGM Study (Diaphragm Pacing System)

The Penn State Hershey Medical Center is taking part in a multicenter research study to collect more information about the possible benefits and risks of the NeuRx Diaphragm Pacing System (DPS)®. The NeuRx DPS® has four electrodes that are implanted into your diaphragm (breathing muscle) during minimally invasive laparoscopic surgery. The electrodes connect to an external device that is intended to stimulate and condition the diaphragm to maintain the ability to breathe as long as possible.

PLSFRS Validation Study

The Penn State Hershey Medical Center is taking part in a multicenter research study to test the reliability and validity of a new functional rating scale called the “PLS Functional Rating Scale,” or PLSFRS. The scale is similar to the ALS Functional Rating Scale – Revised, or ALSFRS-R, that many patients complete as part of their regular care.

PENNANT Study (Acthar Gel)

The Penn State Hershey Medical Center is a participating site in a multicenter clinical trial examining the investigational medication Acthar. H.P. Acthar® Gel (Repository Corticotropin Injection, called Acthar in this form) is a prescription drug approved in the USA by the Food and Drug Administration (FDA) for various uses for example, it is used during an exacerbation or as maintenance treatment in selected cases of systemic lupus erythematosus (SLE). It is not approved to treat ALS. The purpose of this research study is to investigate the efficacy of Acthar in slowing ALS progression.

An Online Mindfulness Intervention for People with ALS and their Caregivers

The primary aim of this project is to create and test an online psychological treatment program based on the Langer Mindfulness construct. This is targeted to improve the quality of life for people with ALS and their caregivers.

Telemedicine Program

In March 2015, our center launched a telemedicine program for people with ALS and their families. This program allows us to stay connected with our ALS patients, even when they can’t travel. Telemedicine visits are done through the use of secure video conferencing over the internet between one or more healthcare providers in Hershey and a patient and their family in their home.

Brain-Computer Interface Technology

Brain-computer interface (BCI) devices may be able to make the quality of life better for those living with ALS by facilitating basic forms of movement control and communication. Working closely with Dr. Steven Schiff and Dr. Andrew Geronimo, our research aims to show how BCI use is affected by disease heterogeneity, and how we can use engineering principles to adapt our systems to optimize BCI use for each user.

Quality of Life

We have a longstanding interest in quality of life (QOL) in patients with ALS. Our group has developed a QOL questionnaire made for those with ALS. It’s called the ALS-Specific Quality of Life Instrument-Revised, or ALSSQOL-R.  The ALS-Specific Quality of Life-Revised (ALSSQOL-R) is available for free to those who would like to use it. View and download the ALSSQOL-R Manual.

We have recently constructed a short form of the tool (ALSSQOL-20) which includes 20 items. The ALSSQOL-20 was recently validated in a multicenter study. A manual will be available soon. View and download the ALSSQOL-20 tool.

We welcome collaboration from other ALS centers for projects using this instrument. Those interested in collaborating should contact Dr. Zachary Simmons at

We’re currently working with investigators in U.S. centers and international centers to understand QOL in patients with different cultural and ethnic backgrounds. We’ve recently constructed a short form of the tool (ALSSQOL-SF) which includes 18 items. We’re in the process of validating the ALSSQOL-SF in a multicenter study.

Turning Research into Practice

Evidence-Based Practice is a method of providing clinical care to patients by systematically incorporating solid research evidence with clinician expertise. This process has inspired several collaborative teams, made up of clinicians and researchers. Each group focuses on a particular aspect of patient care so we can better meet the needs of our patients. Topics include:

Basic science research studies at Penn State

Understanding Cellular Stress and ALS

Studies to understand the relationship between H63D and cellular stress and between H63D and two other mutations known to be associated with ALS — TDP-43 and SOD1 — are in progress. Human cells that carry the H63D mutation have elevated levels of stress and mitochondrial dysfunction and alterations in glutamate metabolism and increased TDP-43 that are thought to contribute to ALS. These models will help us to understand the impact of the mutations on cell function and how the mutations combine to cause cell death, permitting the development of therapeutic strategies around that knowledge.

Genetics of ALS and other Motor Neuron Diseases

Since the creation of the Penn State Institute for Personalized Medicine, this game-changing medical model is driving opportunities for greater collaborations across the institution to advance medical science. In collaboration with Dr. James Broach, and with patient and family member consent, blood and/or saliva samples will be taken and used to conduct highly sophisticated genetic sequencing. The process will identify known or new genetic mutations that are associated with ALS.

To learn more about current clinical trials, visit StudyFinder.

Symptoms, Diagnosis & Outlook

Amyotrophic lateral sclerosis is also known as ALS or Lou Gehrig’s disease. This is a disease of the nerve cells in the brain and spinal cord that control muscle movement. The experts at The Penn State Hershey ALS Clinic provide a definite diagnose and offer complete care that helps the person with ALS function as normally as possible and have a better quality of life.


Symptoms usually don’t start until after age 50, but they can also start in younger people. People with ALS lose muscle strength and coordination over time. Weakness can first affect the arms or legs, or breathing and swallowing. This gets worse and eventually makes it impossible for them to do normal tasks like going up steps, getting out of a chair, or swallowing.

ALS doesn’t affect the senses (sight, smell, taste, hearing, touch). Most patients are able to think normally, although a small number have dementia, which causes problems with memory.

Signs that a person may have ALS

Causes & Risk Factors

Possible complications of ALS

Over time, people with ALS can’t function and care for themselves. Death often occurs within three to five years after diagnosis. About one in five patients live for more than five years after they’re diagnosed. Some patients live much longer, but they may need help breathing from a ventilator or other device.


Patients have a complete examination and their past medical records are reviewed. Using that information, our neurologist orders various tests as needed. These tests may include:


Most patients will also have electrodiagnostic testing (EMG and nerve conduction tests) in our EMG laboratory. Other tests may include:

We can help

To schedule an appointment, please call